Insider Transactions in Q1 2026 at Regenxbio Inc. (RGNX)
Insider Transaction List (Q1 2026)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 06
2026
|
Patrick J. Christmas Chief Strategy & Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
73,749
+25.51%
|
-
|
|
Jan 06
2026
|
Curran Simpson Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
144,864
+29.73%
|
-
|
|
Jan 06
2026
|
Craig Malzahn Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
65,847
+44.48%
|
-
|
|
Jan 06
2026
|
Steve Pakola Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
65,847
+20.31%
|
-
|
|
Jan 06
2026
|
Mitchell Chan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
73,749
+36.61%
|
-
|
|
Jan 02
2026
|
Steve Pakola Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,247
-8.66%
|
$255,458
$14.4 P/Share
|
|
Jan 02
2026
|
Patrick J. Christmas Chief Strategy & Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,793
-6.47%
|
$137,102
$14.4 P/Share
|
|
Jan 02
2026
|
Craig Malzahn Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,238
-7.04%
|
$17,332
$14.4 P/Share
|
|
Jan 02
2026
|
Curran Simpson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,559
-8.59%
|
$259,826
$14.4 P/Share
|